Attorney Docket No.: 6124.200-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anne Charlotte Arentsen

Application No.: To be assigned Group Art Unit: To be assigned

Filed: January 25, 2001 Examiner: To be assigned

For: Crystallisation Of A GLP-1 Analogue

PRELIMINARY AMENDMENT

Commissioner for Patents Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the title, insert

-- CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. 119 of United States provisional application no. 60/183,300 filed on February 17, 2000 and Danish application no PA 2000 00156 filed on January 31, 2000, the contents of which are fully incorporated herein by reference.--

IN THE CLAIMS:

Please amend the claims as follows:

Claim 3, line 1, delete "any one of claims 1-2" and insert --claim 1--. Claim 4, line 1, delete "any one of claims 1-3" and insert --claim 1--.

Claim 5, line 1, delete "any one of claims 1-4" and insert --claim 1--. Claim 6, line 1, delete "any one of claims 1-5" and insert --claim 1--. Claim 7, line 1, delete "anyone of claims 1-6" and insert --claim 1--. Claim 8, line 1, delete "anyone of claims 1-7" and insert --claim 1--. Claim 9, line 1, delete "anyone of claims 1-8" and insert --claim 1--. Claim 10, line 1, delete "anyone of claims 1-9" and insert --claim 1--. Claim 11, line 1, delete "anyone of claims 1-10" and insert --claim 1--.

REMARKS

Claims 1-15 are pending in the present application. The claims have been amended to remove multiple dependencies. No new matter is introduced by this amendment.

Applicants enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing. The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification. No new matter is added.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: January 25, 2001

Valeta A. Gregg, Reg. No. 35. Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 887-9638